Articles related to DRUG EFFICACY

The FDA approved enlicitide, the first oral PCSK9 inhibitor, after phase 3 studies demonstrated substantial LDL-C reductions in patients requiring additional lipid lowering. Cardiovascular outcomes data remain pending.

A single dose of an investigational LSD formulation was associated with greater improvement in depressive symptoms than placebo in a phase 3 trial of adults with major depressive disorder. The findings are based on topline company-reported results and await full peer-reviewed publication.

A randomized noninferiority trial found that oral fosfomycin matched continued intravenous therapy in stabilized patients with ESBL complicated UTIs after 3 to 7 days of initial IV treatment.

A systematic review of 43 randomized controlled trials found high-certainty evidence that multiple CGRP-targeted therapies reduced monthly migraine headache days by approximately 2 days versus placebo in adults with chronic migraine.

The LRRK2 inhibitor BIIB122 failed to slow disease progression versus placebo in 648 early-stage idiopathic Parkinson’s patients in the Phase 2b LUMA trial, leading Biogen and Denali to discontinue joint development.

Neoadjuvant apalutamide plus abiraterone and ADT before radical prostatectomy was associated with improved 12-month potency recovery and lower positive surgical margin rates compared with surgery alone in a small phase 2 trial of men with high-risk localized prostate cancer.